JP2024518426A - 投与レジメン - Google Patents

投与レジメン Download PDF

Info

Publication number
JP2024518426A
JP2024518426A JP2023568475A JP2023568475A JP2024518426A JP 2024518426 A JP2024518426 A JP 2024518426A JP 2023568475 A JP2023568475 A JP 2023568475A JP 2023568475 A JP2023568475 A JP 2023568475A JP 2024518426 A JP2024518426 A JP 2024518426A
Authority
JP
Japan
Prior art keywords
asciminib
imatinib
administered
pharma
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518426A5 (https=
Inventor
ケイ ドッド，ステファニー
ウルカデ－プテルレット，フロレンス
フート，フェリックス
クインラン，ミシェル
ザック，ジュリア
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024518426A publication Critical patent/JP2024518426A/ja
Publication of JP2024518426A5 publication Critical patent/JP2024518426A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023568475A 2021-05-11 2022-05-10 投与レジメン Pending JP2024518426A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187023P 2021-05-11 2021-05-11
US63/187,023 2021-05-11
PCT/IB2022/054321 WO2022238884A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Publications (2)

Publication Number Publication Date
JP2024518426A true JP2024518426A (ja) 2024-05-01
JP2024518426A5 JP2024518426A5 (https=) 2025-05-01

Family

ID=81846537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568475A Pending JP2024518426A (ja) 2021-05-11 2022-05-10 投与レジメン

Country Status (8)

Country Link
US (1) US20240245666A1 (https=)
EP (1) EP4337205A1 (https=)
JP (1) JP2024518426A (https=)
KR (1) KR20240006600A (https=)
CN (1) CN117396202A (https=)
CA (1) CA3218550A1 (https=)
IL (1) IL308095A (https=)
WO (1) WO2022238884A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239604A (zh) * 2023-11-01 2025-07-01 深圳市塔吉瑞生物医药有限公司 治疗白血病的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521185A (ja) * 2012-05-15 2015-07-27 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521185A (ja) * 2012-05-15 2015-07-27 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.134, Suppl.1, JPN6026009524, 2019, pages 5910, ISSN: 0005813230 *
BLOOD, vol. Vol.134, Suppl.1, JPN6026009525, 2019, pages 3879, ISSN: 0005813231 *
IN VIVO, vol. 19, JPN6026009526, 2005, pages 77 - 84, ISSN: 0005813232 *

Also Published As

Publication number Publication date
CN117396202A (zh) 2024-01-12
EP4337205A1 (en) 2024-03-20
WO2022238884A1 (en) 2022-11-17
US20240245666A1 (en) 2024-07-25
CA3218550A1 (en) 2022-11-17
IL308095A (en) 2023-12-01
KR20240006600A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
US9585893B2 (en) Flumazenil complexes, compositions comprising same and uses thereof
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
CN108472275A (zh) 治疗缺血性中风的组合物及方法
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
EP4423071A1 (en) Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
JP5362151B2 (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
WO2000000187A1 (fr) Compositions medicinales destinees au traitement de l'insuffisance d'evacuation
BRPI0616659A2 (pt) droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
JP2024518426A (ja) 投与レジメン
CN110573148A (zh) 特发性肺纤维化的治疗
JPWO2006011397A1 (ja) 糖尿病の予防または治療のための薬剤
JP6068447B2 (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
US20150231127A1 (en) Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
JP2002523363A (ja) 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用
KR20240091327A (ko) 복셀로터를 사용한 겸상 적혈구 질환의 치료 방법
CN110339195A (zh) 用于治疗胆管癌的喹啉衍生物
JP2014513689A (ja) 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物
EP4561574A1 (en) Dosing regimen for a nlrp3 inhibitor
TW202604485A (zh) 患有肝損傷患者肝疾病之治療
KR20100022955A (ko) (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
JPH0228113A (ja) 高尿酸血症改善・治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260311